KRONOS WORLDWIDE, INC. PRICES PRIVATE OFFERING OF AN ADDITIONAL 75 MILLION OF 9.50 percent SENIOR SECURED NOTES DUE 2029
KRON Stock | USD 1.05 0.02 1.87% |
About 62% of Kronos Bio's investor base is looking to short. The analysis of the overall investor sentiment regarding Kronos Bio suggests that many traders are alarmed. Kronos Bio's investing sentiment overview a quick insight into current market opportunities from investing in Kronos Bio. Many technical investors use Kronos Bio stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Kronos |
Dallas, Texas, July 23, 2024 -- Kronos Worldwide, Inc. announced today that its wholly-owned subsidiary, Kronos International, Inc. , has agreed to sell 75 million aggregate principal amount of additional 9.50 percent Senior Secured Notes due 2029 through an institutional private placement. The Notes will be issued as additional notes to the existing 276,174,000 aggregate principal amount of 9.50 percent Senior Secured Notes due 2029 that KII
Read at finance.yahoo.com
Kronos Bio Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Kronos Bio can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Kronos Bio Fundamental Analysis
We analyze Kronos Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kronos Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kronos Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Operating Margin
Operating Margin Comparative Analysis
Kronos Bio is currently under evaluation in operating margin category among its peers. Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Kronos Bio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Kronos Bio stock to make a market-neutral strategy. Peer analysis of Kronos Bio could also be used in its relative valuation, which is a method of valuing Kronos Bio by comparing valuation metrics with similar companies.
Peers
Kronos Bio Related Equities
CYCN | Cyclerion Therapeutics | 2.96 | ||||
NVCT | Nuvectis Pharma | 2.91 | ||||
CCCC | C4 Therapeutics | 2.86 | ||||
ADXN | Addex Therapeutics | 2.30 | ||||
LYEL | Lyell Immunopharma | 2.22 | ||||
SPRO | Spero Therapeutics | 1.75 | ||||
REPL | Replimune | 1.58 | ||||
CRNX | Crinetics Pharmaceuticals | 0.97 | ||||
ACHL | Achilles Therapeutics | 0.96 | ||||
GBIO | Generation Bio | 0.79 | ||||
LYRA | Lyra Therapeutics | 0.48 | ||||
INBX | Inhibrx | 0.27 | ||||
ERAS | Erasca | 0.67 | ||||
MRUS | Merus BV | 1.83 | ||||
EWTX | Edgewise Therapeutics | 2.58 | ||||
NXTC | NextCure | 2.59 | ||||
LRMR | Larimar Therapeutics | 2.81 | ||||
ASMB | Assembly Biosciences | 3.53 | ||||
GOSS | Gossamer Bio | 3.90 | ||||
CTMX | CytomX Therapeutics | 3.97 |
Check out Kronos Bio Hype Analysis, Kronos Bio Correlation and Kronos Bio Performance. To learn how to invest in Kronos Stock, please use our How to Invest in Kronos Bio guide.You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kronos Bio. If investors know Kronos will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kronos Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.43) | Revenue Per Share 0.143 | Quarterly Revenue Growth 0.442 | Return On Assets (0.28) | Return On Equity (0.63) |
The market value of Kronos Bio is measured differently than its book value, which is the value of Kronos that is recorded on the company's balance sheet. Investors also form their own opinion of Kronos Bio's value that differs from its market value or its book value, called intrinsic value, which is Kronos Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kronos Bio's market value can be influenced by many factors that don't directly affect Kronos Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Kronos Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Kronos Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kronos Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.